Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

被引:87
作者
Brettschneider, J
Petzold, A
Junker, A
Tumani, H
机构
[1] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany
[2] Inst Neurol, Dept Neuroinflammat, London WC1N 3BG, England
关键词
axonal damage; cerebrospinal fluid; clinically isolated syndrome; multiple sclerosis; neurofilaments; tau protein;
D O I
10.1191/135248506ms1263oa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinically isolated syndrome (CIS) represents the earliest phase of multiple sclerosis ( MS). This study tested whether biomarkers for axonal degeneration can improve upon sensitivity and specificity of magnetic resonance imaging (MRI) parameters in predicting conversion from CIS to MS. Patients with CIS ( n = 52), relapsing-remitting MS ( RRMS, n = 38) and age-matched controls ( n = 25) were included. Cerebrospinal fluid (CSF) levels of tau and neurofilaments (NfH(SMI35)) were measured using ELISA. The MRI T2-lesion load and the Expanded Disability Status Scale (EDSS) were recorded. CSF tau and NfH(SMI35) were elevated in CIS compared to controls (P< 0.05). RRMS patients with acute relapse had higher NfH(SMI35) levels than stable patients. Tau and NfH(SMI35) levels correlated with EDSS in CIS and RRMS. In RRMS, the number of T2-lesions correlated with tau levels ( R = 0.53, P = 0.01). The sensitivity predicting the conversion from CIS to MS was higher for the combination of CSF markers ( either tau or NfH(SMI35) elevated) than for MRI ( 40 versus 34%), but could be further increased to 60% if CSF and MRI criteria were combined. Similarly, the combination of tau and NfH(SMI35) showed higher specificity (94%) than MRI (82%). Tau and NfHSMI35 are valuable biomarkers for axonal damage in the CIS patients. Predicting conversion from CIS to MS can be improved if CSF markers are combined with MRI.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 37 条
[11]   Multiple sclerosis - Neurofilament light chain antibodies are correlated to cerebral atrophy [J].
Eikelenboom, MJ ;
Petzold, A ;
Lazeron, RHC ;
Silber, E ;
Sharief, M ;
Thompson, EJ ;
Barkhof, F ;
Giovannoni, G ;
Polman, CH ;
Uitdehaag, BMJ .
NEUROLOGY, 2003, 60 (02) :219-223
[12]   CRITERIA FOR AN INCREASED SPECIFICITY OF MRI INTERPRETATION IN ELDERLY SUBJECTS WITH SUSPECTED MULTIPLE-SCLEROSIS [J].
FAZEKAS, F ;
OFFENBACHER, H ;
FUCHS, S ;
SCHMIDT, R ;
NIEDERKORN, K ;
HORNER, S ;
LECHNER, H .
NEUROLOGY, 1988, 38 (12) :1822-1825
[13]   Management of acute optic neuritis [J].
Hickman, SJ ;
Dalton, CM ;
Miller, DH ;
Plant, GT .
LANCET, 2002, 360 (9349) :1953-1962
[14]   Increased cerebrospinal fluid tau protein in multiple sclerosis [J].
Kapaki, E ;
Paraskevas, GP ;
Michalopoulou, M ;
Kilidireas, K .
EUROPEAN NEUROLOGY, 2000, 43 (04) :228-232
[15]   ISOELECTRIC-FOCUSING OF CEREBROSPINAL-FLUID IMMUNOGLOBULIN-G - AN ANNOTATED UPDATE [J].
KEIR, G ;
LUXTON, RW ;
THOMPSON, EJ .
ANNALS OF CLINICAL BIOCHEMISTRY, 1990, 27 :436-443
[16]   Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time [J].
Kuhlmann, T ;
Lingfeld, G ;
Bitsch, A ;
Schuchardt, J ;
Brück, W .
BRAIN, 2002, 125 :2202-2212
[17]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[18]   Cerebrospinal fluid levels of brain specific proteins in optic neuritis [J].
Lim, ET ;
Grant, D ;
Pashenkov, M ;
Keir, G ;
Thompson, EJ ;
Söderström, M ;
Giovannoni, G .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (03) :261-265
[19]   Spinal cord atrophy and disability in multiple sclerosis - A new reproducible and sensitive MRI method with potential to monitor disease progression [J].
Losseff, NA ;
Webb, SL ;
ORiordan, JI ;
Page, R ;
Wang, L ;
Barker, GJ ;
Tofts, PS ;
McDonald, WI ;
Miller, DH ;
Thompson, AJ .
BRAIN, 1996, 119 :701-708
[20]   Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis [J].
Lycke, JN ;
Karlsson, JE ;
Andersen, O ;
Rosengren, LE .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :402-404